8EQ logo

Cytek Biosciences DB:8EQ Stock Report

Last Price

€6.55

Market Cap

€858.8m

7D

24.8%

1Y

92.6%

Updated

13 Nov, 2024

Data

Company Financials +

8EQ Stock Overview

A cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. More details

8EQ fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Cytek Biosciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cytek Biosciences
Historical stock prices
Current Share PriceUS$6.55
52 Week HighUS$6.90
52 Week LowUS$4.20
Beta1.32
11 Month Change45.56%
3 Month Change38.19%
1 Year Change92.65%
33 Year Change-67.25%
5 Year Changen/a
Change since IPO-68.05%

Recent News & Updates

Recent updates

Shareholder Returns

8EQDE Life SciencesDE Market
7D24.8%1.7%-0.2%
1Y92.6%9.0%7.8%

Return vs Industry: 8EQ exceeded the German Life Sciences industry which returned 10.6% over the past year.

Return vs Market: 8EQ exceeded the German Market which returned 9% over the past year.

Price Volatility

Is 8EQ's price volatile compared to industry and market?
8EQ volatility
8EQ Average Weekly Movement11.5%
Life Sciences Industry Average Movement6.1%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.7%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 8EQ's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 8EQ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
1992645Wenbin Jiangcytekbio.com

Cytek Biosciences, Inc., a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems. The company also provides reagents and kits, including cFluor reagents that are fluorochrome conjugated antibodies used to identify cells of interest for analysis on its instruments, as well as 25-color immunoprofiling assay that provides turnkey solutions for identifying major human immune subpopulations for TBNK cells, monocytes, dendritic cells, and basophils.

Cytek Biosciences, Inc. Fundamentals Summary

How do Cytek Biosciences's earnings and revenue compare to its market cap?
8EQ fundamental statistics
Market cap€858.76m
Earnings (TTM)-€9.62m
Revenue (TTM)€190.55m

4.3x

P/S Ratio

-86.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
8EQ income statement (TTM)
RevenueUS$201.21m
Cost of RevenueUS$90.71m
Gross ProfitUS$110.50m
Other ExpensesUS$120.66m
Earnings-US$10.16m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.079
Gross Margin54.92%
Net Profit Margin-5.05%
Debt/Equity Ratio0.8%

How did 8EQ perform over the long term?

See historical performance and comparison